GSK Buys Tesaro For $5 Billion In Dramatic Bet On Cancer Genetics


GlaxoSmithKline announced this morning that it will buy Tesaro, the maker of the ovarian cancer drug Zejula, for $5.1 billion in cash in a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock market.


- Advertisement -